NOVEL BIOLOGY
PATIENT IMPACT

Immunitas was founded to discover and develop novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 for treatment of solid tumors and hematological malignancies. Our second program, recently licensed to Boehringer Ingelheim, is a novel therapeutic for the treatment of autoimmune disease.

OUR BIOLOGY

Immunitas was founded by a team of highly renowned cancer research and therapeutic antibody pioneers from Dana Farber Cancer Institute, Mass General Cancer Center, the Broad Institute, and MIT. That team identified CD161 as a compelling T cell target for oncology. Their findings were published in Cell in 2021.

 

NEWS & EVENTS

May 12, 2026

Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases

 

April 17, 2026

Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

 

April 17, 2026

A First in Human, Dose Escalation and Biomarker Cohort Expansion of IMT-009 (anti CD161) in advanced cancer and Phase 1b combination with Fruquintinib in Microsatellite Stable Colorectal Cancer

 

March 17, 2026

Immunitas Therapeutics to Present Clinical Data Supporting Monotherapy and Combination Treatment Potential of IMT-009 at the AACR 2026 Annual Meeting

 

July 30, 2025

IMT-380: A first in class anti-CD161 antibody targeting Pathogenic T Cells in Autoimmune Diseases

 

July 30, 2025

Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity

 

April 8, 2024

Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

 

April 8, 2024

Abundance of KLRB1+ (CD161) T cells in anti-PD1 non responders coupled with enhanced tumor cytotoxicity of anti-CD161 (IMT-009) with anti-PD1 makes it a rational target for combination with anti-PD-(L)1 immunotherapy

 

March 5, 2024

Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

 

January 18, 2024

Immunitas Therapeutics Appoints Annalisa D’Andrea, Ph.D., as Chief Scientific Officer

 

December 4, 2023

Immunitas Therapeutics Announces Appointment of James Wooldridge as Chief Medical Officer and Upcoming Presentation at ASH 2023 Annual Meeting

 

November 3, 2023

Immunitas Therapeutics Presents New Data for TLR9 Agonist Conjugate at the Society for Immunotherapy of Cancer 2023 Annual Meeting

 

November 3, 2023

Anti CLEC2D-TLR9 agonist conjugate binds to and internalizes CLEC2D on myeloid cells, plasmacytoid Dendritic cells and B cells leading to robust TLR pathway activation and inflammatory cytokine production

 

October 31, 2023

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting

 

January 4, 2023

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

 

November 11, 2022

Immunitas Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Cancer Immunotherapy IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

 

November 11, 2022

2022 SITC Annual Meeting:  Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D

 

October 5, 2022

Immunitas Therapeutics to Present Preclinical Data on IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

 

September 21, 2022

Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies

 

July 13, 2022

Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer

 

March 9, 2022

Immunitas Therapeutics to Present at Festival of Biologics 2022

 

November 16, 2021

Immunitas Therapeutics Names Amanda Wagner as CEO

 
 
Mask Group 10.png

August 18, 2021

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

 
 

CONTACT

 

Immunitas Therapeutics, Inc.
Boston, MA

info@immunitastx.com